Mobile

An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease

Mise à jour : Il y a 4 ans
Référence : GSK100468

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild to moderate Alzheimer's disease who have completed 24 weeks of treatment in the AVA100193 study.

Critère d'inclusion

  • mild to moderate Alzheimer's Disease

Liens